1
|
García A, Cámara JA, Boullosa AM, Gustà MF, Mondragón L, Schwartz S, Casals E, Abasolo I, Bastús NG, Puntes V. Nanoceria as Safe Contrast Agents for X-ray CT Imaging. Nanomaterials (Basel) 2023; 13:2208. [PMID: 37570527 PMCID: PMC10421217 DOI: 10.3390/nano13152208] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 07/24/2023] [Accepted: 07/27/2023] [Indexed: 08/13/2023]
Abstract
Cerium oxide nanoparticles (CeO2NPs) have exceptional catalytic properties, rendering them highly effective in removing excessive reactive oxygen species (ROS) from biological environments, which is crucial in safeguarding these environments against radiation-induced damage. Additionally, the Ce atom's high Z number makes it an ideal candidate for utilisation as an X-ray imaging contrast agent. We herein show how the injection of albumin-stabilised 5 nm CeO2NPs into mice revealed substantial enhancement in X-ray contrast, reaching up to a tenfold increase at significantly lower concentrations than commercial or other proposed contrast agents. Remarkably, these NPs exhibited prolonged residence time within the target organs. Thus, upon injection into the tail vein, they exhibited efficient uptake by the liver and spleen, with 85% of the injected dose (%ID) recovered after 7 days. In the case of intratumoral administration, 99% ID of CeO2NPs remained within the tumour throughout the 7-day observation period, allowing for observation of disease dynamics. Mass spectrometry (ICP-MS) elemental analysis confirmed X-ray CT imaging observations.
Collapse
Affiliation(s)
- Ana García
- Design and Pharmacokinetics of Nanoparticles, CIBBIM-Nanomedicine, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (A.G.); (L.M.)
| | - Juan Antonio Cámara
- Preclinical Imaging Platform, Vall d’Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain;
| | - Ana María Boullosa
- Clinical Biochemistry, Drug Delivery & Targeting (CB-DDT), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (A.M.B.); (I.A.)
- Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08034 Barcelona, Spain; (M.F.G.); (N.G.B.)
| | - Muriel F. Gustà
- Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08034 Barcelona, Spain; (M.F.G.); (N.G.B.)
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), 08036 Barcelona, Spain
| | - Laura Mondragón
- Design and Pharmacokinetics of Nanoparticles, CIBBIM-Nanomedicine, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (A.G.); (L.M.)
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), 08036 Barcelona, Spain
| | - Simó Schwartz
- Clinical Biochemistry, Drug Delivery & Targeting (CB-DDT), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (A.M.B.); (I.A.)
- Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08034 Barcelona, Spain; (M.F.G.); (N.G.B.)
- Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
| | - Eudald Casals
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China;
| | - Ibane Abasolo
- Clinical Biochemistry, Drug Delivery & Targeting (CB-DDT), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (A.M.B.); (I.A.)
- Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08034 Barcelona, Spain; (M.F.G.); (N.G.B.)
- Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
| | - Neus G. Bastús
- Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08034 Barcelona, Spain; (M.F.G.); (N.G.B.)
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), 08036 Barcelona, Spain
| | - Víctor Puntes
- Design and Pharmacokinetics of Nanoparticles, CIBBIM-Nanomedicine, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain; (A.G.); (L.M.)
- Networking Research Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08034 Barcelona, Spain; (M.F.G.); (N.G.B.)
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), 08036 Barcelona, Spain
- Institut Català de Recerca i Estudis Avançats, (ICREA), P. Lluis Companys 23, 08010 Barcelona, Spain
| |
Collapse
|
2
|
Gustà MF, Edel MJ, Salazar VA, Alvarez-Palomo B, Juan M, Broggini M, Damia G, Bigini P, Corbelli A, Fiordaliso F, Barbul A, Korenstein R, Bastús NG, Puntes V. Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles. Front Immunol 2023; 14:1128582. [PMID: 37228592 PMCID: PMC10205015 DOI: 10.3389/fimmu.2023.1128582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 04/21/2023] [Indexed: 05/27/2023] Open
Abstract
Introduction Gene therapy holds promise to cure various diseases at the fundamental level. For that, efficient carriers are needed for successful gene delivery. Synthetic 'non-viral' vectors, as cationic polymers, are quickly gaining popularity as efficient vectors for transmitting genes. However, they suffer from high toxicity associated with the permeation and poration of the cell membrane. This toxic aspect can be eliminated by nanoconjugation. Still, results suggest that optimising the oligonucleotide complexation, ultimately determined by the size and charge of the nanovector, is not the only barrier to efficient gene delivery. Methods We herein develop a comprehensive nanovector catalogue comprising different sizes of Au NPs functionalized with two different cationic molecules and further loaded with mRNA for its delivery inside the cell. Results and Discussion Tested nanovectors showed safe and sustained transfection efficiencies over 7 days, where 50 nm Au NPs displayed the highest transfection rates. Remarkably, protein expression was increased when nanovector transfection was performed combined with chloroquine. Cytotoxicity and risk assessment demonstrated that nanovectors are safe, ascribed to lesser cellular damage due to their internalization and delivery via endocytosis. Obtained results may pave the way to design advanced and efficient gene therapies for safely transferring oligonucleotides.
Collapse
Affiliation(s)
- Muriel F. Gustà
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
- Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Michael J. Edel
- Hospital Clínic de Barcelona, Servei Immunologia-IDIBAPS, Barcelona, Spain
- Unit of Anatomy and Embryology, Universitat Autònoma de Barcelona, Faculty of Medicine, Barcelona, Spain
- University of Western Australia, Faculty of Medicine, Discipline of Medical Sciences and Genetics, School of Biomedical Sciences, Perth, WA, Australia
| | - Vivian A. Salazar
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
| | | | - Manel Juan
- Hospital Clínic de Barcelona, Servei Immunologia-IDIBAPS, Barcelona, Spain
| | - Massimo Broggini
- IRCCS‐Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Giovanna Damia
- IRCCS‐Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Paolo Bigini
- IRCCS‐Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | | | - Fabio Fiordaliso
- IRCCS‐Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Alexander Barbul
- Tel Aviv University, Sackler School of Medicine, Tel Aviv-Yafo, Israel
| | - Rafi Korenstein
- Tel Aviv University, Sackler School of Medicine, Tel Aviv-Yafo, Israel
| | - Neus G. Bastús
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Víctor Puntes
- Institut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
- Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| |
Collapse
|
3
|
Ernst LM, Mondragón L, Ramis J, Gustà MF, Yudina T, Casals E, Bastús NG, Fernández-Varo G, Casals G, Jiménez W, Puntes V. Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration. Antioxidants (Basel) 2023; 12:antiox12030765. [PMID: 36979013 PMCID: PMC10045098 DOI: 10.3390/antiox12030765] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 03/14/2023] [Accepted: 03/16/2023] [Indexed: 03/30/2023] Open
Abstract
Nanoparticle (NP) pharmacokinetics significantly differ from traditional small molecule principles. From this emerges the need to create new tools and concepts to harness their full potential and avoid unnecessary risks. Nanoparticle pharmacokinetics strongly depend on size, shape, surface functionalisation, and aggregation state, influencing their biodistribution, accumulation, transformations, and excretion profile, and hence their efficacy and safety. Today, while NP biodistribution and nanoceria biodistribution have been studied often at short times, their long-term accumulation and excretion have rarely been studied. In this work, 3 nm nanoceria at 5.7 mg/kg of body weight was intravenously administrated in a single dose to healthy mice. Biodistribution was measured in the liver, spleen, kidney, lung, brain, lymph nodes, ovary, bone marrow, urine, and faeces at different time points (1, 9, 30, and 100 days). Biodistribution and urinary and faecal excretion were also studied in rats placed in metabolic cages at shorter times. The similarity of results of different NPs in different models is shown as the heterogeneous nanoceria distribution in organs. After the expectable accumulation in the liver and spleen, the concentration of cerium decays exponentially, accounting for about a 50% excretion of cerium from the body in 100 days. Cerium ions, coming from NP dissolution, are most likely excreted via the urinary tract, and ceria nanoparticles accumulated in the liver are most likely excreted via the hepatobiliary route. In addition, nanoceria looks safe and does not damage the target organs. No weight loss or apathy was observed during the course of the experiments.
Collapse
Affiliation(s)
- Lena M Ernst
- Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain
| | - Laura Mondragón
- Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain
- Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain
| | - Joana Ramis
- Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain
| | - Muriel F Gustà
- Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain
- Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Tetyana Yudina
- Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain
| | - Eudald Casals
- Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China
| | - Neus G Bastús
- Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain
- Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Guillermo Fernández-Varo
- Service of Biochemistry and Molecular Genetics, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Gregori Casals
- Service of Biochemistry and Molecular Genetics, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
- Department of Fundamental Care and Medical-Surgical Nursing, Universitat de Barcelona, 08007 Barcelona, Spain
| | - Wladimiro Jiménez
- Service of Biochemistry and Molecular Genetics, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
- Departament de Biomedicina, Universitat de Barcelona, 08007 Barcelona, Spain
| | - Victor Puntes
- Vall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain
- Institut Català de Nanociència I Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193 Barcelona, Spain
- Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain
| |
Collapse
|